Ravandi, Farhad <br/><br/>
Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation.  [electronic resource] 

 -  Blood  Jun 2013 
 - 4655-62 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1528-0020 
<br/><br/><label>Standard No.: </label>10.1182/blood-2013-01-480228  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Combined Chemotherapy Protocols--blood<br/>Azacitidine--administration & dosage<br/>Feasibility Studies<br/>Female<br/>Follow-Up Studies<br/>Humans<br/>Leukemia, Myeloid, Acute--drug therapy<br/>Male<br/>Middle Aged<br/>Mutation--genetics<br/>Neoplasm Recurrence, Local--drug therapy<br/>Niacinamide--administration & dosage<br/>Phenylurea Compounds--administration & dosage<br/>Prognosis<br/>Remission Induction<br/>Sorafenib<br/>Survival Rate<br/>Tandem Repeat Sequences--genetics<br/>Young Adult<br/>fms-Like Tyrosine Kinase 3--antagonists & inhibitors